Current Trends in Collaborative Drug Research: Leveraging target validation data to create valuable partnerships – Feb. 16, 2022

Session Description

Part III of the “Jump Start: Early-Stage Technology Development in Precision Medicine” Workshop Series

During this session our speakers will present and discuss the significance of target validation for early-stage drug discovery and development in academic settings using adMare BioInnovations and U of T IPO approaches (e.g., Bright Angel Therapeutics, Encycle Therapeutics, Zucara Therapeutics). You will learn how target validation increases likelihood of success in the clinic, important considerations during early-stage drug discovery, and the added value of bringing in valuable partnerships with Industry. This session aims to stimulate commercial thinking during research and discovery phase.

The goal of PRiME’s Jump Start series is to provide a deep dive into all steps in development of pre-clinical drugs, devices and platforms. We plan to invite experts who will discuss their views on the importance of each step.

These workshops are open to all Trainees and Principal Investigators.